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This study analyzed changes in patients, transplantation, graft characteristics, and outcome among 827 pa-
tients who received their ﬁrst allo-SCT in a single center between 1983 and 2010. In the 2001 to 2010 decade,
compared with the 1983 to 1990 and 1991 to 2000 decades, patients were signiﬁcantly older and presented
with higher risk diseases, reduced intensity conditioning and alternative donors were used more often, and
stem cell sources changed from bone marrow to peripheral blood stem cells and cord blood. In the 2001 to
2010 decade, we observed a signiﬁcant decrease in nonrelapse mortality (NRM) (P ¼ .0007 and P < .0001,
respectively) and an increase in relapse incidence (P ¼ .04 and P ¼ .009, respectively), but overall survival (OS)
was increased (P ¼ .11 and P ¼ .009, respectively), and there was a trend towards an increased progression-
free survival (P ¼ .30 and P ¼ .09, respectively), as compared with the 1983 to 1990 and 1991 to 2000 decades.
Chronic graft-versus-host disease (GVHD) was signiﬁcantly increased, whereas grades III to IV acute GVHD
remained stable. These data suggest that, despite the fact that older and higher risk patients with more
comorbidities underwent transplantation in the last 10 years, NRM decreased while the incidence of relapse
increased and the OS improved.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION advent of reduced-intensity conditioning (RIC) regimens
Allogeneic hematopoietic stem cell transplantation (allo-
SCT) is an effective therapy for different life-threatening
malignant and nonmalignant diseases. However, this treat-
ment is limited by high morbidity and mortality, mainly
related to infection, graft-versus-host disease (GVHD), and
conditioning-related toxicity. Fortunately, since its intro-
duction in the early 70s [1], important progress has been
made in allo-SCT, leading to a reduced nonrelapse mortality
(NRM). Indeed, signiﬁcant innovations have emerged in
supportive care for prevention or treatment of GVHD, fungal
infections, and viral reactivations. Further advances in allo-
SCT were represented by the development of new types of
grafts [2,3] and the use of alternative donors [4]. Finally, thedgments on page 1222.
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14.04.021[5,6] has led to a signiﬁcant development of various in-
dications, especially in patients whowere usually considered
not eligible for allo-SCT because of their age or their
comorbidities. Our hypothesis was that all these changes in
the care of allo-SCT patients, implemented in our center over
the past 3 decades, have improved outcome. We, therefore,
compared the cumulative incidence of NRM, relapse, acute
and chronic GVHD, overall survival (OS), and progression-
free survival (PFS) in 3 successive cohorts of patients who
underwent transplantation in a single-center academic
transplantation program from 1983 through 1990, from 1991
through 2000, and from 2001 through 2010.
PATIENTS AND METHODS
Patients and Study Design
This retrospective single-center study included patients who underwent
their ﬁrst allo-SCT at the University Hospital of Nantes (Nantes, France)
between 1983 and 2010. For the purpose of this study, only patients aged
over 18 years at time of transplantation were included. As part of standard
practice, patients and donors gave their approval for use of their data for
research purposes. The study was approved by the local institutional review
board.
Transplantation Techniques
All patients received a preparative regimen followed by the infusion of
donor cells as inpatients in private rooms, and they remained hospitalized
until hematopoietic and clinical recovery. The myeloablative conditioning
(MAC) regimens generally contained high-dose cyclophosphamide and
either 12 Gy of total body irradiation (TBI) or busulfan. Reduced-intensityTransplantation.
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or ﬂudarabine, low-dose busulfan, and antithymocyte globulin (ATG). In our
transplantation program, eligibility criteria for RIC allo-SCT included the
following: (1) patient age older than 50 years, (2) patients whowere heavily
pretreated andwho received auto-SCTor more than 2 lines of chemotherapy
before allo-SCT, and (3) patients with poor performance status because of
signiﬁcant medical comorbidities, as conﬁrmed in 2007 by Sorror et al. [7].
For GVHD prophylaxis, patients received cyclosporine A (CsA) alone until
1986 and then in association with methotrexate for MAC [8]. For RIC, GVHD
prophylaxis consisted of CsA alone in the case of a matched sibling donor or
CsA and mycophenolate mofetil in the case of an alternative donor [9]. CsA
was administered at a dose of 3 mg/kg/day by continuous intravenous
infusion starting from day 3 or 2, and changed to twice daily oral dosing
as soon as tolerated [10]. Prophylaxis against infection included acyclovir or
valacyclovir for Herpes simplex virus [11,12], trimethoprim and/or sulfa-
methoxazole for Pneumocystis jirovecii, and oral penicillin against encap-
sulated bacteria [13]. In patients with neutropenia, empiric broad-spectrum
antibiotics were begun for a temperature greater than 38.3C or clinical
signs of infection. Patients with cytomegalovirus infection received pre-
emptive therapy with ganciclovir from 1989 or valganciclovir from 2002Table 1
Study Population Characteristics
Characteristic (%) All (N ¼ 827) 1983-1990
(n ¼ 103)
1991-2000
(n ¼ 221)
Patient age, median (range) 45.0 (18.0-70.7) 32.2 (18.5-62.6) 38.8 (18.0-63
Patient gender
Male 484 (58.5) 55 (52.8) 127 (57.0)
Female 343 (41.5) 48 (47.2) 94 (43.0)
Diagnosis
Myeloid malignancies 421 (50.9) 70 (69.4) 120 (55.3)
AML 249 (30.1) 39 (39.8) 67 (31.6)
MDS 53 (6.4) 3 (2.8) 9 (3.8)
MPN 31 (3.7) 2 (1.9) 4 (1.7)
CML 83 (10.0) 26 (25.0) 40 (18.1)
CMML 5 (0.6) 0 0
Lymphoid malignancies 386 (46.7) 29 (26.9) 95 (42.2)
NHL 143 (17.3) 7 (6.5) 23 (10.1)
HD 29 (3.5) 1 (0.9) 2 (0.8)
CLL 36 (4.4) 2 (1.9) 7 (3.0)
MM 68 (8.2) 5 (4.6) 18 (7.6)
ALL 110 (13.3) 14 (13.0) 45 (20.7)
Aplastic anemia 20 (2.4) 4 (3.7) 6 (2.5)
Disease status
Standard risk 226 (27.3) 42 (38.9) 82 (35.5)
High risk 581 (70.3) 57 (57.4) 133 (62.0)
NA 20 (2.4) 4 (3.7) 6 (2.5)
HLA matching
Matched related donor 527 (64.1) 92 (89.8) 181 (83.1)
Alternative donor 300 (35.9) 11 (10.2) 40 (16.9)
Stem cell source
Bone marrow 403 (49.4) 103 (100) 195 (86.9)
PBSC 368 (43.9) 0 26 (13.1)
CB 54 (6.7) 0 0
Conditioning regimen
Myeloablative 465 (56.0) 103 (100) 207 (92.4)
Reduced-intensity
conditioning
362 (44.0) 0 14 (7.6)
High-dose TBI-based
conditioning
regimen
Yes 394 (45.5) 86 (78.7) 195 (83.1)
No 433 (54.5) 17 (21.3) 26 (16.9)
ATG-based conditioning
regimen
Yes 296 (35.6) 2 (1.9) 20 (9.3)
No 531 (64.4) 101 (98.1) 201 (90.7)
GVHD prophylaxis
CsA alone (þ/CS) 238 (28.8) 35/2 (35.2) 14 (5.9)
CsA þ MMF (þ/CS) 187 (22.4) 0 0
CsA þ MTX 402 (48.8) 68/7 (64.8) 207 (94.1)
AML indicates acute myeloid leukemia; MDS, myelodysplastic syndrome; MPN, my
myelo monocytic leukemia; NHL, non-Hodgkin lymphoma; HD, hodgkin disease
lymphoblastic leukemia; NA, not applicable; PBSC, peripheral blood stem cells; CB
cyclosporine A; CS, corticosteroids; MMF, mycophenolate mofetil; MTX, methotre
* Four patients from this cohort received both PBSC and bone marrow.[14,15]. Patients with Epstein-Barr virus DNA levels exceeding 1000 copies/
105 cells on 2 or more occasions were preemptively treated with rituximab
to prevent Epstein-Barr viruserelated lymphoproliferative diseases from
2004 [16,17]. For fungal infections, patients received prophylactic therapy
with ﬂuconazole from 1992 [18]; in RIC regimens, ﬂuconazole was dis-
continued after 2007. The majority of patients received intravenous heparin
(100 UI/kg/day) until the absolute neutrophil count reached 500/mL to
prevent veno-occlusive disease [19].Outcome Measurements
Outcome measurements included OS, PFS, NRM, relapse, and the fre-
quency and severity of acute and chronic GVHD. The database was locked on
January 31, 2013. For NRM, we considered all deaths occurring after allo-SCT
that were not caused by relapse or progression of the underlying disease.
The severity of acute GVHD was graded according to the Glucksberg clas-
siﬁcation [20,21]. The severity of chronic GVHD was graded as limited or
extensive, according to the historical classiﬁcation [22]; because of the
retrospective nature of our study and its spread over time, we were not able
to apply the National Institutes of Health revised criteria [23].P Value (1991-
2000 versus
1983-1990)
2001-2010
(n ¼ 503)
P Value (2001-
2010 versus
1983-1990)
P Value (2001-
2010 versus
1991-2000)
.7) <.0001 52.0 (18.2-70.7) <.0001 <.0001
.49 .21 .52
302 (60.4)
201 (39.6)
.03 <.0001 .07
231 (46.5)
143 (28.6)
41 (8.7)
25 (4.8)
17 (3.3)
5 (1.0)
262 (51.4)
113 (21.8)
26 (5.2)
27 (5.4)
45 (8.7)
51 (10.2)
10 (2.1)
.62 <.0001 <.0001
102 (19.9)
391 (71.0)
10 (2.4)
.10 <.0001 <.0001
254 (50)
249 (50)
<.0001 <.0001 <.0001
105 (21.6)
342 (67.2)*
54 (11.2)
.0006 <.0001 <.0001
155 (30.1)
348 (69.9)
.29 <.0001 <.0001
113 (21.4)
390 (78.6)
.02 <.0001 <.0001
274 (54.6)
229 (45.4)
<.0001 <.0001 <.0001
189/3 (38.0)
187/3 (37.3)
127/1 (24.7)
eloproliferative neoplasm; CML, chronic myeloid leukemia; CMML, chronic
; CLL, chronic lymphocytic leukemia; MM, multiple myeloma; ALL, acute
, cord blood; TBI, total body irradiation; ATG, antithymocyte globulin; CsA,
xate.
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OS and PFS were calculated by the Kaplan-Meier method and subgroups
were compared using the log-rank test. For categorical variables, compari-
son between groups was carried out using the chi-square test for patient
gender and the Fisher exact test for diagnosis, disease status at trans-
plantation, stem cell source, donor type, conditioning regimen, use of TBI,
use of ATG, GVHD prophylaxis, acute GVHD occurrence, graft failure, and
cause of death. For continuous data (patient age and median follow-up), the
comparisons were performed using the Mann-Whitney test. Probabilities of
relapse, NRM, and chronic GVHD were calculated using the cumulative
incidence procedure and comparisons were performed using the Gray test.
All data were computed using GraphPad Prism 5.0 (GraphPad Software, San
Diego, CA) and the R package (R Development Core Team, 2006. R: A lan-
guage and environment for statistical computing. R Foundation for Statis-
tical Computing, Vienna, Austria. http://www.R-project.org).RESULTS
Patient Characteristics
Patient disease and transplantation characteristics for the
entire study population and for each decade group are
detailed in Table 1. The median age of patients who received
allo-SCT increased from32.2 years (range,18.1 to 62.6) for the
1983 to 1990 decade to 38.8 (range, 18.0 to 63.7) for the 1991
to 2000 decade (P< .0001) and up to 52.0 years (range,18.2 to
70.7) (P< .0001) for the 2001 to 2010 decade (Figure 1A). The
sex ratio remained stable over decades, with a slight male
predominance (sex ratio, 1.41). The proportion of aplastic
anemia and acute leukemia among diseases treated by allo-
SCT remained the same over the 3 decades, whereas the
proportion of lymphoid malignancies increased and, as ex-
pected, the proportion of chronic myeloid leukemia patients
who underwent transplantation decreased (Figure 1F).
With regards to disease status at transplantation, there
was a signiﬁcant increase of high-risk disease (diseaseFigure 1. Study population characteristics. (A) Median patient age at transplantation b
decade (MAC, myeloablative conditioning; RIC, reduced-intensity conditioning). (C)
ripheral blood stem cells; BM, bone marrow). (D) Proportions of donor types by decad
of disease indications for allo-SCT by decade (AA, aplastic anemia; LYM, all lymphoid
leukemia; AL, acute myeloblastic leukemia and acute lymphoblastic leukemia).beyond ﬁrst complete remission in case of acute leukemia
and ﬁrst chronic phase for chronic myeloid leukemia), from
57.4% and 62.0%, for the 1983 to 1990 and the 1991 to
2000 decades, respectively, to 71.0% for the 2001 to
2010 decade (P < .0001 for both comparisons) (Figure 1E).
In terms of stem cell source, unmanipulated bonemarrow
(BM) was used in all patients during 1983 to 1990 and in the
majority during 1991 to 2000; peripheral blood stem cells
(PBSC) began to be used in the 1991 to 2000 decade in 13.1%
of patients before being used in the majority of patients in
the 2001 to 2010 decade (67.2%), when BMwas the source of
transplantation cells in only 21.6% of patients, with the
remaining 11.2% corresponding to unrelated cord blood
transplantations (Figure 1C). We saw an increase in the
number of alternative donors from 10.2% and 16.9% in the
1983 to 1990 and 1991 to 2000 decades, respectively, to
50.0% in the 2001 to 2010 decade (P < .0001 for both com-
parisons) (Figure 1D).
All patients received theMAC conditioning regimen in the
1983 to 1990 decade, with RIC appearing during the 1991 to
2000 decade (7.6%) and constituting the predominant
regimen (69.9%) from 2001 to 2010 (Figure 1B). Subse-
quently, the use of high-dose TBIebased conditioning
regimen decreased from 78.7% and 83.1% in the 1983 to 1990
and 1991 to 2000 decades, respectively, to 21.4% in the most
recent decade (P < .0001 for both comparisons). Conversely,
the use of ATG-based conditioning regimen increased from
1.9% and 9.3% in the 1983 to 1990 and 1991 to 2000 decades,
respectively, to 54.6% in the 2001 to 2010 decade (P < .0001
for both comparisons).
Finally, GVHD prophylaxis saw a signiﬁcant reduction in
the use of CsA þ methotrexate from 64.8% and 94.1% in they decade of transplantation. (B) Proportions of type of conditioning regimen by
Proportions of type of stem cell source by decade (CB, cord blood; PBSC, pe-
e. (E) Proportions of disease status at transplantation by decade. (F) Proportions
malignancies except for acute lymphoblastic leukemia; CML, chronic myeloid
Table 2
Transplantation-related Events
Characteristic (%) All (N ¼ 827) 1983-1990
(n ¼ 103)
1991-2000
(n ¼ 221)
P Value (1991-
2000 versus
1983-1990)
2001-2010
(n ¼ 503)
P Value (2001-
2010 versus
1983-1990)
P Value (2001-
2010 versus
1991-2000)
Follow-up, median (range), yr 6.8 (.64-26.0) 21.0 (6.7-26.0) 12.6 (1.7-19.3) <.0001 5.0 (.6-11.5) <.0001 <.0001
OS .88 .11 .009
At 2 yr (95% CI) 56.4 (52.9-59.7) 52.4 (42.4-61.5) 51.6 (44.8-57.9) 59.3 (54.9-63.5)
At 5 yr (95% CI) 50.5 (47.0-54.0) 46.6 (36.8-55.9) 45.6 (39.0-52.1) 53.5 (48.9-57.9)
PFS .86 .30 .09
At 2 yr (95% CI) 49.7 (46.2-53.1) 45.6 (35.8-54.9) 47.1 (40.4-53.5) 51.6 (47.1-55.9)
At 5 yr (95% CI) 42.0 (38.5-45.4) 39.8 (30.4-49.1) 38.0 (31.6-44.4) 44.5 (40.0-48.9)
NRM .52 .0007 <.0001
At 2 yr (cumulative incidence) 26.5% 35.9% 34.9% 20.9%
At 5 yr (cumulative incidence) 29.7% 37.9% 39.5% 23.7%
Acute GVHD at days 100
Grade 2-4 34.6% 27.2% 37.6% .08 34.8% .50 .17
Grade 3-4 19.2% 14.6% 24.0% .06 18.1% .48 .07
Overall chronic GVHD .30 <.0001 <.0001
At 2 yr (cumulative incidence) 32.7% 12.6% 21.7% 41.6%
At 5 yr (cumulative incidence) 35.1% 15.5% 25.4% 43.3%
Extensive chronic GVHD .33 .04 .0005
At 2 yr (cumulative incidence) 16.4% 8.7% 8.6% 21.5%
At 5 yr (cumulative incidence) 17.7% 11.6% 10.4% 21.9%
Relapse/progression .82 .04 .009
At 2 yr (cumulative incidence) 25.8% 19.4% 20.4% 29.5%
At 5 yr (cumulative incidence) 31.6% 25.2% 26.7% 34.8%
Primary graft failure 38 (4.6) 8 (7.8) 7 (3.2) .11 23 (4.6) .69 .20
Secondary graft failure 4 (.5) 1 (1.0) 1 (.5) 2 (.4)
Cause of death <.0001
GVHD 85 (9.9) 15 (13.0) 22 (10.1) 68 (9.0)
Infection 78 (9.0) 13 (12.0) 36 (15.6) 29 (5.4)
Other transplantation-related
cause
97 (20.3) 19 (34.4) 39 (30.8) .69 39 (12.9) .0001
Relapse/progression 171 (18.0) 16 (13.9) 38 (16.0) 117 (19.7)
OS indicates overall survival; CI, conﬁdence interval; PFS, progression-free survival; NRM, nonrelapse mortality; GVHD, graft-versus-host disease.
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24.7% in the 2001 to 2010 decade (P < .0001 for both com-
parisons), with the introduction of the CsAþmycophenolate
mofetil prophylaxis (37.3%) in the latter decade.
Outcome
Transplantation-related events are summarized in
Table 2. The overall median follow-up was 6.8 (range, .64 to
26.0) years among surviving patients. Of the 827 patients
included in this study, 431 died during the follow-up decade
and 396 are still alive at last follow-up (2-year OS of 56.4%
[95% conﬁdence interval (CI), 52.9% to 59.7%]). The 2-year OS
was comparable between the 1983 to 1990 and 1991 to
2000 decades (52.4% [95% CI, 42.4% to 61.5%] versus 51.6%
[95% CI, 44.8% to 57.9%]; P ¼ .88), but it was signiﬁcantly
better (59.3% [95% CI, 54.9% to 63.5%]) in the 2001 to 2010 as
compared with the 1991 to 2000 decade (P ¼ .009)
(Figure 2A). Similarly, there was no signiﬁcant difference in
PFS at 2 years between the 1983 to 1990 and the 1991 to
2000 decades (45.6% [95% CI, 35.8% to 54.9%] versus 47.1%
[95% CI, 40.4% to 53.5%]; P¼ .860), and only a trend towards a
better PFS in the 2001 to 2010 decade (51.6% [95% CI, 47.1% to
55.9%]) as compared with 1991 to 2000 (P ¼ .09) (Figure 2B).
At 2 years, the overall cumulative incidence of NRM was
26.5%. These rates were similar in the 1983 to 1990 and 1991
to 2000 decades (35.9% and 34.9%, respectively; P ¼ .86) but
signiﬁcantly decreased to 20.9% in the 2001 to 2010 decade
(P ¼ .0007 and P < .0001 for 1983 to 1990 and 1991 to 2000,
respectively) (Figure 2C). The cumulative incidence of
relapse or progression at 2 years after allo-SCT was also
comparable between the 1983 to 1990 and the 1991 to
2000 decades (19.4% and 20.4%, respectively; P¼ .82) but was
signiﬁcantly higher, at 29.5%, during the 2001 to 2010 decade(P ¼ .04 and P ¼ .009 for 1983 to 1990 and 1991 to 2000,
respectively) (Figure 2D). There was a trend towards a higher
incidence of severe grade 3 to 4 acute GVHD during the 1991
to 2000 decade as compared with the 1983 to 1990 and 2001
to 2010 decades (24.0% versus 14.6% [P ¼ .06] and 18.1% [P ¼
.07] for 1983 to 1990 and 2001 to 2010, respectively)
(Figure 2E). The cumulative incidence of extensive chronic
GVHD at 2 years was similar in the 1983 to 1990 and 1991 to
2000 decades (8.7% and 8.6%, respectively; P ¼ .33), but
signiﬁcantly higher (21.5%) during the 2001 to 2010 decade
(P ¼ .04 and P ¼ .0005 for 1983 to 1990 and 2001 to 2010,
respectively) (Figure 2F).DISCUSSION
In this study, we observed a signiﬁcant decrease in NRM
over decades. However, such decrease was counterbalanced
by a signiﬁcant increase in the cumulative incidence of
relapse or progression, though OS improved signiﬁcantly in
the 2001 to 2010 decade, and there was a trend towards an
improvement in PFS. An important change in allo-SCT prac-
tice in the most recent decade was the introduction and
predominant use of the RIC regimen, at the expense of the
classical MAC regimen, since 2001 in our center. Conse-
quently high-dose TBI was less used and ATG was increas-
ingly employed as part of the RIC regimen. This explains, at
least in part, the increase observed in the relapse rate, which
has always been shown to be higher after RIC than after MAC
[24]. Furthermore, patients who underwent transplantation
during the 2001 to 2010 decade were older and had more
advanced disease than those who underwent trans-
plantation in the earlier decades, contributing to the
increased risk of relapse.
Figure 2. Outcome after allo-SCT by decade. (A) Overall survival. (B) Disease-free survival. (C) Cumulative incidence of NRM. (D) Cumulative incidence of relapse. (E)
Proportion of grade 0 to 1, grade 2, and grade 3 to 4 acute GVHD by decade. (F) Cumulative incidence of extensive chronic GVHD.
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major changes were also observed between the ﬁrst 2 de-
cades and the 2001 to 2010 decade, with the introduction
granulocyte colonyestimulating factoremobilized PBSC
grafts and the use of unrelated cord blood cells. Furthermore,
whereas matched related donors were used for 80% to 90% of
patients, the 2001 to 2010 decade saw the advent of trans-
plantations from alternative donors, with the use of cells
from unrelated donors and of umbilical cord blood in adult
patients. This is explained by the greater availability of un-
related donors, with the donor registry network now
encompassing more than 20 million potential donors
worldwide. Furthermore, whereas matched unrelated donor
transplantations were initially associated with an increased
incidence of GVHD [25], progress in HLA typing and match-
ing [26] has reduced this risk, and several studies reported a
similar outcome between transplantations from HLA-
matched related and 10/10 HLA-matched unrelated donors
[27,28]. As for cord blood, it was ﬁrst employed in our center
for transplantation of an adult patient in 2003. As expected,
the use of cord blood was characterized by a high incidenceof infectious complications [29] and it was initially consid-
ered only in patients with high-risk diseases. However, the
results have progressively improved, and cord blood is now
considered for patients who lack a matched related or un-
related donor [30]. Haploidentical allo-SCT was not per-
formed in our center at time of the current study [31].
The increased cumulative incidence of overall and
extensive chronic GVHD in the 2001 to 2010 decade is
probably explained by the increased use of unrelated donors
and of PBSC and the higher age of patients, all of which are
well-known risk factors for chronic GVHD [32,33]. Never-
theless, the increased rate of chronic GVHD was probably
limited by the large use of ATG in the 2001 to 2010 decade,
which is increasingly proven to exert a protective effect
against severe chronic GVHD [34-36]. Furthermore, despite
the increase in chronic GVHD, fewer patients died of this
complication in the 2001 to 2010 decade, reﬂecting the
progress achieved in the prophylaxis and treatment of GVHD
[37]. On the contrary, the decreased use of TBI and of MAC
[38], 2 well-established risk factors of acute GVHD, led to a
stability of acute GVHD, despite the increased used of
F. Malard et al. / Biol Blood Marrow Transplant 20 (2014) 1217e12231222unrelated donors [33]. Likewise, in spite of the older age of
patients with higher-risk diseases and the use of cord blood
grafts [29] and of ATG, there were fewer deaths consequent
to infection in the 2001 to 2010 decade because of improved
methods of prophylaxis and treatment of infectious
complications.
In conclusion, this large retrospective study highlights the
recent progress that took place in the daily practice of allo-
SCT, outside of clinical trials. Indeed, the development of
RIC regimens and the improvement in supportive care for
prevention or treatment of GVHD, fungal infection, and viral
reactivation allowed us to performed allo-SCT in older pa-
tients, in those with comorbidities, and in those who have
received more chemotherapy with, consequently, more
advanced diseases. Although this incurred a price of a higher
risk of relapse, the NRMwas signiﬁcantly reduced, leading to
an improvement in OS. The challenge in the next decade will
be to decrease this risk of relapse while the number of high-
risk allo-SCT procedure increases. Indeed, use of new graft
sources, such as haplo-mismatched grafts, widespread and
older patients with comorbidities or multiple pre-
transplantation treatments are considered for allo-SCT. The
use of posteallo-SCT preventive strategies based on
chemotherapy, hypomethylating agents [39], or immuno-
therapy [40] seem promising to prevent relapse in these
patients. Furthermore, monitoring of minimal residual dis-
ease after allo-SCT will allow early detection of recurrence
and subsequent intervention before clinically detectable
relapse, not only in the setting of acute myeloid leukemia,
myelodysplastic syndrome [41], and acute lymphoblastic
leukemia but also in lymphoid malignancies and multiple
myeloma [42]. Similarly, the development of cytoreductive
agents with an optimized tolerance proﬁle will probably
allow increasing the intensity of myeloablation delivered as
part of a RIC regimen and will, subsequently, decrease the
relapse rate, without increasing NRM. Thus, Alatrash et al.
reported promising results after a myeloablative reduced-
toxicity regimen based on i.v. busulfan and ﬂudarabine in
acute myeloid leukemia patients older than 55 years [43].
Overall, the development of new graft sources will allow the
performance of allo-SCT in almost all eligible patients, as this
remains the only proven form of curative treatment in many
hematologic malignancies.
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